Sildenafil and The Pharmaceutical Industry: A Dangerous Bet?

The legacy of the blue pill offers a intricate case study for investors eyeing pharma. While initial sales were remarkable, recent patent expiry and the rise of cheaper versions have significantly affected earnings. Moreover, increasing regulatory examination and calls to reduce medication prices pose continuous challenges. Consequently, betting on

read more

Premium Roller The Pill: A Risky Wager

The emergence of so-called "High Roller Viagra" – often referring to exceptionally high doses ordered by unscrupulous physicians – represents a troublingly alarming trend. While typical dosages of the medication are intended for treating erectile dysfunction safely in most men, these significantly elevated doses pose a significant threat to cir

read more